Clinical Trials in Detroit

Showing 10821-10840 of 19,719 trials

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

NCT01504711

This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.

Gastrointestinal CancerNausea Post Chemotherapy

Philip Philip30 participantsStarted Jun 2012

Detroit, Michigan, United States

COMPLETED12 miles

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

NCT04829552

This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.

Covid19

Corewell Health East704 participantsStarted Mar 2020

Royal Oak, Michigan, United States

COMPLETEDPhase 313 miles

Essure (Model ESS310) Placement Rate Study

NCT02064413

To evaluate the safety and successful placement rate of Essure Model ESS310 device and any factors that may influence the successful placement rate of this device.

Contraception

Bayer134 participantsStarted Mar 2014

Glendale, Arizona, United States • Phoenix, Arizona, United States • Colorado Springs, Colorado, United States +13 more locations

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

Essure (Model ESS310) Placement Rate Study

Find Trials by Condition in Detroit

Augmenting rTMS With Cognitive Control Training in Major Depressive Disorder

Rheos System for the Treatment of HFpEF Heart Failure

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Peer Led Asthma Self Management for Adolescents: PLASMA

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors